MRCF invests in Australian antibiotics start-up Auspherix

3 December 2013

Auspherix Pty, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease was launched today in Australia with A$1 million ($913,826) in start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF).

Auspherix will in-license intellectual property from the ithree institute at the University of Technology Sydney (UTS), emerging from research led by Ian Charles, Director of the ithree institute together with Dagmar Alber, ithree senior research fellow. Prof Charles and Dr Alber previously worked together at the successful UK anti-infectives company Arrow Therapeutics, of which Prof Charles was a co-founder.

The ithree team has been exploring new ways to treat bacterial infections that have become resistance to currently available antibiotics. It has used a library screening approach to identify drugs with novel mechanisms of action as antibiotics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical